Avid Bioservices Inc (CDMO)

[Habitual]

CTO

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 30, 2013
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Peregrine Pharmaceuticals, Inc.
File No. 001-32839 - CF#30142
_____________________
Peregrine Pharmaceuticals, Inc. submitted an application under Rule 24b-2
requesting an extension of a previous grant of confidential treatment for information it
excluded from the Exhibits to a Form 10-Q filed on September 9, 2010.
Based on representations by Peregrine Pharmaceuticals, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following
exhibits will not be released to the public for the time periods specified:
Exhibit 10.26 through September 9, 2016
Exhibit 10.27 through September 9, 2016
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Elizabeth M. Murphy
Secretary